These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17845588)

  • 1. CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment.
    Nopp A; Johansson SG; Ankerst J; Palmqvist M; Oman H
    Allergy; 2007 Oct; 62(10):1175-81. PubMed ID: 17845588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. After 6 years with Xolair; a 3-year withdrawal follow-up.
    Nopp A; Johansson SG; Adédoyin J; Ankerst J; Palmqvist M; Oman H
    Allergy; 2010 Jan; 65(1):56-60. PubMed ID: 19796193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation.
    Nopp A; Johansson SG; Ankerst J; Bylin G; Cardell LO; Grönneberg R; Irander K; Palmqvist M; Oman H
    Allergy; 2006 Mar; 61(3):298-302. PubMed ID: 16436137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
    Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
    J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basophil allergen threshold sensitivity, CD-sens, is a measure of allergen sensitivity in asthma.
    Dahlén B; Nopp A; Johansson SG; Eduards M; Skedinger M; Adédoyin J
    Clin Exp Allergy; 2011 Aug; 41(8):1091-7. PubMed ID: 21518044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations.
    Slavin RG; Ferioli C; Tannenbaum SJ; Martin C; Blogg M; Lowe PJ
    J Allergy Clin Immunol; 2009 Jan; 123(1):107-113.e3. PubMed ID: 19130931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Passive IgE-sensitization by blood transfusion.
    Johansson SG; Nopp A; van Hage M; Olofsson N; Lundahl J; Wehlin L; Söderström L; Stiller V; Oman H
    Allergy; 2005 Sep; 60(9):1192-9. PubMed ID: 16076307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair) treatment.
    Johansson SGO; Nopp A; Öman H; Ankerst J; Cardell LO; Grönneberg R; Matsols H; Rudblad S; Strand V; Stålenheim G
    Allergy; 2009 Oct; 64(10):1472-1477. PubMed ID: 19393000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High basophil allergen sensitivity (CD-sens) is associated with severe allergic asthma in children.
    Konradsen JR; Nordlund B; Nilsson OB; van Hage M; Nopp A; Hedlin G; Grönlund H
    Pediatr Allergy Immunol; 2012 Jun; 23(4):376-84. PubMed ID: 22432913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD-sens: a biological measure of immunological changes stimulated by ASIT.
    Nopp A; Cardell LO; Johansson SG; Oman H
    Allergy; 2009 May; 64(5):811-4. PubMed ID: 19220221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy.
    Hamilton RG; Marcotte GV; Saini SS
    J Immunol Methods; 2005 Aug; 303(1-2):81-91. PubMed ID: 16045925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.
    Lin H; Boesel KM; Griffith DT; Prussin C; Foster B; Romero FA; Townley R; Casale TB
    J Allergy Clin Immunol; 2004 Feb; 113(2):297-302. PubMed ID: 14767445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical follow-up of omalizumab in routine treatment of allergic asthma monitored by CD-sens.
    Johansson SGO; Lilja G; Hallberg J; Nopp A
    Immun Inflamm Dis; 2018 Sep; 6(3):382-391. PubMed ID: 29737044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics.
    Noga O; Hanf G; Kunkel G; Kleine-Tebbe J
    Int Arch Allergy Immunol; 2008; 146(1):66-70. PubMed ID: 18087163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
    Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
    Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Xolair is effective in allergics with a low serum IgE level.
    Ankerst J; Nopp A; Johansson SG; Adédoyin J; Oman H
    Int Arch Allergy Immunol; 2010; 152(1):71-4. PubMed ID: 19940508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Omalizumab (Xolair). Product description].
    Laursen LC
    Ugeskr Laeger; 2007 Mar; 169(11):993-5. PubMed ID: 17371630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated.
    Ogino S; Nagakura T; Okubo K; Sato N; Takahashi M; Ishikawa T
    Int Arch Allergy Immunol; 2009; 149(3):239-45. PubMed ID: 19218816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases.
    D'Amato G
    Eur J Pharmacol; 2006 Mar; 533(1-3):302-7. PubMed ID: 16464445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.